Investor Interest in Biotechs Continues

Shutterstock photo

Interest in novel therapeutics continues, evidenced by the announcement by oncology biotech Turning Point ( TPTX ) that it increased the number of shares by 20% to 8.8 million, giving it a market cap of $547 million and $237 million in cash.

Turning Point is developing second generation tyrosine kinase inhibitors (TKI), with its lead candidate repotrectinib in a 75-patient Phase 1 trial for non-small cell lung cancer (NSCLC). 

Here are three things you should know about Turning Point.

 To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.

Start a Free Trial of IPO Pro

The article Investor Interest in Biotechs Continues originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: TPTX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?